Bcr-Abl
Gli inibitori di Bcr-Abl sono terapie mirate che inibiscono la proteina di fusione Bcr-Abl, formata a seguito della traslocazione del cromosoma Philadelphia e responsabile della leucemia mieloide cronica (CML). Questa proteina influenza anche l'angiogenesi, contribuendo alla progressione tumorale. Gli inibitori di Bcr-Abl sono cruciali nel trattamento della CML e sono oggetto di ricerca per il loro potenziale nell'inibire l'angiogenesi in vari tipi di cancro. Presso CymitQuimica, offriamo inibitori di Bcr-Abl di alta qualità per supportare la tua ricerca in biologia del cancro, angiogenesi e terapie mirate.
Trovati 113 prodotti di "Bcr-Abl"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
cSRC/BCR-ABL1-IN-1
cSRC/BCR-ABL1-IN-1 (compound 16a) is a dual-target inhibitor of the cSRC/BCR-ABL1 kinases.Formula:C24H27ClN6O4Colore e forma:SolidPeso molecolare:498.96BCR-ABL-IN-9
BCR-ABL-IN-9 (Compound B1) is an inhibitor of BCR-ABL that achieves sustained suppression through the formation of stable covalent bonds with the ABL kinase. It effectively inhibits the activity of ABL kinase (IC50 = 1.2 nM) and possesses anticancer activity.Formula:C22H20N4O3Colore e forma:SolidPeso molecolare:388.42HG-7-85-01-NH2
CAS:HG-7-85-01-NH2, as the ligand for SNIPER(ABL)-033, effectively induces the reduction of BCR-ABL protein. This is achieved through SNIPER(ABL)-033, which connects HG-7-85-01 (an ABL inhibitor) to an LCL161 derivative (an IAP ligand) using a linker, demonstrating a DC50 value of 0.3 μM [1].Formula:C27H27F3N6OSColore e forma:SolidPeso molecolare:540.6c-ABL-IN-1
CAS:C-ABL-IN-1 is a new and specific inhibitor of the c-Abl protein, which effectively prevents the progression of neurodegeneration observed in Parkinson's diseaseFormula:C17H16Cl2FN3OSColore e forma:SolidPeso molecolare:400.29Asciminib hydrochloride
CAS:Asciminib hydrochloride is a STAMP inhibitor targeting the ABL myristoyl pocket, applied in Ph+ CML research for selective oncogenic signaling modulation.Formula:C20H19Cl2F2N5O3Purezza:99.91%Colore e forma:SolidPeso molecolare:486.3BGG463
CAS:BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with an IC50 of 0.25 μM, 0.09 μM and 0.590 μM, respectively.Formula:C30H29F3N6O3Purezza:98.21% - >99.99%Colore e forma:SolidPeso molecolare:578.58GNF-7
CAS:GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.Formula:C28H24F3N7O2Purezza:97.05% - 99.7%Colore e forma:SolidPeso molecolare:547.53Degrasyn
CAS:Degrasyn (WP1130) inhibits DUBs (USP5, UCH-L1, USP9x, USP14, UCH37) and Bcr/Abl without affecting the 20S proteasome.Formula:C19H18BrN3OPurezza:98.32% - 99.98%Colore e forma:SolidPeso molecolare:384.27Nocodazole
CAS:Nocodazole: synthetic microtubule polymerization blocker, also impedes Abl with low IC50; binds to beta-tubulin.Formula:C14H11N3O3SPurezza:98% - 99.91%Colore e forma:Physical Description White Powder (Ntp 1992)Peso molecolare:301.32Rebastinib
CAS:<p>DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC,</p>Formula:C30H28FN7O3Purezza:99.53% - 99.79%Colore e forma:SolidPeso molecolare:553.59Ponatinib
CAS:Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectivelyFormula:C29H27F3N6OPurezza:98% - 99.60%Colore e forma:SolidPeso molecolare:532.56NVP-BAW2881
CAS:NVP-BAW2881 (BAW2881) is a potent and selective VEGFR inhibitor with activity to inhibit chronic and acute skin inflammation.Formula:C22H15F3N4O2Purezza:98.19% - 99.97%Colore e forma:SolidPeso molecolare:424.38AT9283
CAS:<p>AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).</p>Formula:C19H23N7O2Purezza:99.83% - 99.98%Colore e forma:SolidPeso molecolare:381.43Multi-kinase inhibitor 1
CAS:<p>Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.</p>Formula:C20H17F3N4O3Purezza:99.34%Colore e forma:SolidPeso molecolare:418.37Flumatinib
CAS:Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.Formula:C29H29F3N8OPurezza:99.39% - 99.95%Colore e forma:SolidPeso molecolare:562.59AG1024
CAS:AG1024 (Tyrphostin) suppresses IGF-1R autophosphorylation(IC50=7 μM), and is less potent for IR(IC50=57 μM).Formula:C14H13BrN2OPurezza:98% - 99.37%Colore e forma:SolidPeso molecolare:305.17Olverembatinib dimesylate
CAS:Olverembatinib dimesylate (GZD824 Dimesylate) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I).Formula:C29H27F3N6O·2CH4O3SPurezza:97.66% - >99.99%Colore e forma:SolidPeso molecolare:724.77Dasatinib N-oxide
CAS:<p>Dasatinib N-oxide is a key metabolite and potential impurity of the kinase inhibitor dasatinib.</p>Formula:C22H26ClN7O3SPurezza:98.54% - 99.94%Colore e forma:SolidPeso molecolare:504Olverembatinib
CAS:Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).Formula:C29H27F3N6OPurezza:98.53% - >99.99%Colore e forma:SolidPeso molecolare:532.56NVP-BHG712
CAS:NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src andFormula:C26H20F3N7OPurezza:97.32% - 98.63%Colore e forma:SolidPeso molecolare:503.48
